Divis Laboratories Ltd Quarterly Results

Q2 FY26-27 Results Summary

Revenue

The revenue stands at ₹3,676.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 19.35 per cent from ₹3,080.00 crore. This corresponds to a year-on-year *(YoY) growth of 35.40 per cent.

Operating Profit

Operating Profit stands at ₹1,566.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 24.78 per cent from ₹1,255.00 crore. This corresponds to a year-on-year *(YoY) growth of 76.35 per cent.

PBDT

PBDT stands at ₹1,647.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 25.44 per cent from ₹1,313.00 crore. This corresponds to a year-on-year *(YoY) growth of 60.68 per cent.

Profit Before Tax

Profit Before Tax stands at ₹1,505.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 27.54 per cent from ₹1,180.00 crore. This corresponds to a year-on-year *(YoY) growth of 65.02 per cent.

Net Profit

Net Profit stands at ₹1,127.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 24.94 per cent from ₹902.00 crore. This represents a 63.57 per cent year-on-year *(YoY) growth for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Divis Laboratories Ltd Earnings

CategoryQ2 FY26-27Q2 FY25-26Change %FY25-26FY24-25Change %
Total Revenue3,676.002,715.0035.4010,560.009,360.0012.82
Expenses2,110.001,827.0015.497,193.006,392.0012.53
Other Income94.00145.00-35.17507.00352.0044.03
Operating Profit1,566.00888.0076.353,874.003,320.0016.69
Depreciation142.00113.0025.66463.00402.0015.17
Interest13.008.0062.5023.002.001050.00
Profit Before Tax1,505.00912.0065.023,388.002,916.0016.19
Tax378.00223.0069.51868.00799.008.64
Net Profit1,127.00689.0063.572,568.002,191.0017.21
CategoryQ2 FY26-27Q1 FY26-27Change %
Total Revenue3,676.003,080.0019.35
Expenses2,110.001,825.0015.62
Other Income94.0064.0046.88
Operating Profit1,566.001,255.0024.78
Depreciation142.00133.006.77
Interest13.006.00116.67
Profit Before Tax1,505.001,180.0027.54
Tax378.00278.0035.97
Net Profit1,127.00902.0024.94

Divis Laboratories Ltd Research Reports

ActionTarget Price (₹)BrokerDateReports
Buy 7,375Sharekhan11-Dec-2025
Neutral 6,925Motilal Oswal10-Nov-2025
Neutral 6,320Motilal Oswal07-Aug-2025
Buy 7,225Edelweiss Securities19-May-2025
Neutral 6,200Motilal Oswal04-Feb-2025

Divis Laboratories Ltd Financial Reports

Data not available.

Divis Laboratories Ltd Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Divi's Lab.-0.41%-3.32%21.78%29.85%60.14%71.53%
Sun Pharma.Inds.0.12%-0.77%7.30%-1.35%-0.52%4.94%
Torrent Pharma.-0.71%-1.72%1.93%-7.48%4.06%24.35%
Laurus Labs-0.77%-3.05%12.59%28.50%72.64%135.16%
Zydus Lifesci.-0.64%-0.87%7.37%8.14%17.28%28.44%

Divis Laboratories Ltd Corporate Information

Chairman & Independent Directo: Ramesh B V Nimmagadda
Executive Director & MD: Murali K Divi
Executive Director: N V Ramana
Executive Director / Whole Time Director / CEO: Kiran S Divi
ED / WTD - Commercial: Nilima Prasad Divi
Executive Director / Whole Time Director: S. Devendra Rao
Independent Non Exe. Director: S Ganapaty
Independent Non Exe. Director: Sunaina Singh
Independent Non Exe. Director: Kosaraju Veerayya Chowdary
Independent Non Exe. Director: Rajendrakumar Premchand Shah
Company Sec. & Compli. Officer: Satish Choudhury

Divis Laboratories Ltd News

Brokerages expect diagnostic majors to sustain volume growth through FY27, aided by robust demand and stable pricing, though the recent stock rally may cap upside

Updated On: 21 Sep 2026 | 6:40 PM IST

Till Nifty holds below 23,700, weakness could extend towards 23,500, then 23,400 levels, while on the upside, hurdles can be seen at 23,800, then 23,900 zones.

Updated On: 09 Sep 2026 | 7:49 AM IST

India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.

Updated On: 26 Aug 2026 | 11:11 AM IST

Chandan Taparia of MOFSL recommends buying Divi's Laboratories, TVS Motors and Dixon Technologies, citing strong technical setups and improving momentum.

Updated On: 26 Aug 2026 | 7:49 AM IST

Chandan Taparia of Motilal Oswal Financial Services has recommended three stocks to buy today: Divi's Laboratories, MCX, and Eternal.

Updated On: 12 Aug 2026 | 7:45 AM IST

In the past month, Divi's Labs outperformed the market by soaring 25 per cent, as against a 1.2 per cent rise in the BSE Sensex.

Updated On: 03 Aug 2026 | 12:31 PM IST

Q1FY27 company results: Firms including Aarti Surfactants, Aditya Birla Lifestyle Brands, APL Apollo Tubes, and Utkarsh Small Finance Bank are also to release their April-June earnings today

Updated On: 01 Aug 2026 | 8:15 AM IST

The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.

Updated On: 31 Jul 2026 | 3:05 PM IST

Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.

Updated On: 30 Jul 2026 | 12:31 PM IST

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

Updated On: 20 Jul 2026 | 2:43 PM IST
More